Thursday , 30 June 2022

Assessment of Health Related Quality of Life Indices in Patients on Antidepressant Pharmacotherapy: An Observational Study

Gudipalli Bhavani Tejaswini1*, B. Kumar2
1PG Research Scholar, Department of Pharmacy Practice, Ratnam Institute of Pharmacy, Nellore, A.P.
2Professor, Department of Pharmacy Practice, Ratnam Institute of Pharmacy, Nellore, A.P.

A B S T R A C T
Pharmacotherapy with antidepressants and/ or anti-psychotics helps to relieve depression and improve the mental health and overall quality of life of individuals suffering from this disease. There is sufficient data from clinical trials that show the safety and efficacy of these medications. However there is lack of clear guidelines for prescribing these medications and there is a gap in literature on studies which determine the effect of these medications on the overall wellbeing of individuals. This retrospective, observational study used the Medical Expenditure Panel Survey database. Individuals suffering from depression (ICD-9-CM: 296, 300, and 311) and those taking antidepressants and/or antipsychotics since the beginning of the panel were identified. A total of 804 patients met the study inclusion criteria, among which 688 patients were on monotherapy and 116 on add-on/switch therapy. Among patients only on monotherapy, no significant difference was observed in their tendency to show improvement or decline on PCS-12, K6 and PR-MHS scores based on the class of antidepressants. The results of the study may imply that further research needs to be done to determine the reason for SSRIs to show greater improvement on mental health as compared to SNRIs. Similar results in patients on monotherapy and add-on/switch therapy can suggest that their therapy may keep depressive symptoms under control, which can indicate a good clinical decision by the patients’ health care providers.
Keywords: Pharmacotherapy, clinical trials, PR-MHS, ICD-9-CM, PR-MHS, Antidepressant

Scroll To Top